Subfoveal choroidal thickness after brolucizumab therapy for neovascular age-related macular degeneration: a short-term multicenter study.

Tamaki TamashiroKoji TanakaKanako ItagakiMakiko NakayamaIchiro MarukoSorako WakugawaNobuhiro TeraoHajime OnoeYu WakatsukiMasashi OgasawaraYukinori SuganoAkiko YamamotoKeiko KataokaTakahiko IzumiMoeko KawaiRyusaburo MoriTetsuju SekiryuAnnabelle A OkadaTomohiro IidaHideki Koizuminull null

Published in: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (2022)

Intravitreal injections of brolucizumab for neovascular AMD significantly reduced the SCT in both the treatment-naïve and switched groups. Brolucizumab may cause significant anatomic changes in the choroid, particularly in treatment-naïve AMD eyes, possibly more than that previously reported for other anti-VEGF agents.

Keyphrases

age related macular degeneration
optical coherence tomography
vascular endothelial growth factor
endothelial cells
replacement therapy
smoking cessation